Universitaetsklinikum Muenster AöR

At Universitaetsklinikum Muenster AöR, clinical trials in cardiovascular disease and diagnostic techniques are exploring better care for people with acute ischemic stroke, high-risk transient ischemic attack, and proximal deep vein thrombosis. These studies focus on testing new treatments and improving how clot-related conditions are managed.

• New therapies aimed at reducing stroke risk and improving recovery
• Treatments designed to support clot dissolution in vein thrombosis
• Research on safer, more effective approaches to vascular disease care

The work combines treatment evaluation with efforts to strengthen diagnosis and risk reduction in urgent vascular conditions.

This site is active in neoplasm research across digestive system diseases, hemic and lymphatic diseases, and broader cancer care. Trials include studies in esophageal carcinoma, endometrial carcinoma, prostate cancer, acute myeloid leukemia, multiple myeloma, classical Hodgkin lymphoma, and Ewing sarcoma, with a strong emphasis on improving treatment effectiveness and disease control.

• Testing new cancer therapies and combinations for solid tumors
• Evaluating treatment strategies in leukemia, lymphoma, and myeloma
• Studying ways to improve survival, response, and long-term disease management

Several trials at Universitaetsklinikum Muenster AöR are aimed at refining cancer care for both adults and younger patients.

A major research focus is prostate cancer, including metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, oligometastatic prostate cancer, and PSMA PET scan positive CRPC. These trials are assessing new therapies, hormone-based treatment approaches, and advanced imaging to better detect and monitor disease.

• Evaluating targeted treatments for advanced prostate cancer
• Testing combinations that may improve disease control and survival
• Using PSMA-based imaging to improve detection of spread and guide care

The prostate cancer program blends diagnostic and therapeutic research to support more precise, personalized management.

The site also contributes to studies in children and young adults with cancers such as classical Hodgkin lymphoma, acute myeloid leukemia, and Ewing sarcoma. These trials are designed to improve event-free survival and refine treatment approaches for younger patients facing aggressive disease.

• Optimizing treatment for pediatric and adolescent blood cancers
• Assessing therapy adjustments to improve long-term outcomes
• Supporting research that balances effectiveness with tolerability in younger patients

These studies reflect a strong commitment to advancing age-specific cancer care at Universitaetsklinikum Muenster AöR.

Trials in immune system diseases and cancer are examining new treatment options that harness immunotherapy and targeted agents. Research includes patients with esophageal carcinoma, endometrial carcinoma, and several advanced cancers, with the goal of improving response rates and survival.

• Testing immunotherapy approaches for difficult-to-treat cancers
• Evaluating targeted treatment strategies to slow disease progression
• Studying whether newer combinations can improve overall outcomes

These investigations help expand treatment choices for patients whose cancers need more effective options.

In hematology, the clinical trial portfolio includes studies in acute myeloid leukemia, multiple myeloma, and other blood cancers, along with research that supports treatment selection and disease monitoring. Some trials also examine how to improve outcomes after intensive therapy or transplant-related care.

• Comparing treatment strategies for leukemia and myeloma
• Studying markers of disease response and residual disease
• Exploring ways to improve survival and reduce relapse risk

This area brings together diagnostic and therapeutic research to improve blood cancer management across different patient groups.